Evaluation of ICL670, a Once-Daily Oral Iron Chelator in a Phase III Clinical Trial of ?-Thalassemia Patients with Transfusional Iron Overload
Abstract: Osteoporosis and osteopenia are frequent complications of thalassemia major (TM) and intermedia (TI). Osteoporosis was found in 23/25 patients with TI and in 115/239 patients with TM. In TM, no association was found with specific polymorphisms in candidate genes (vitamin D receptor, estrogen receptor, calcitonin receptor, and collagen type 1 alpha 1). Osteoporosis in TM female was strongly associated with primary amenorrhea (P < .0001), while in male patients with TM hypogonadism was not significantly related to BMD (P= .0001). Low BMD was also associated with cardiomiopathy (P= .01), diabetes mellitus (P= .0001), chronic hepatitis (P= .0029), and increased ALT (P= .01).
iron chelator ?-thalassemia iron overload deferasirox (icl670) pediatrics